2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.
Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.
One promising therapy is ONT-380 (tucatinib), which is currently under investigation in three phase I studies in combination with other anti-HER2 therapies. ONT-380 is similar to lapatinib (Tykerb), though the latter is fraught with several toxicities, says Yardley.
So far, ONT-380 has demonstrated good penetrance into the CNS, and patients treated with the agent have been stable, asymptomatic, and are generally tolerating the drug well in combination with trastuzumab (Herceptin).
Related Content: